Recently, Johnson&Johnson Medical Technology has made organizational adjustments to its surgical division. Starting from January 1, 2025, the Surgery Division will be reorganized into six major departments: Minimally Invasive and Energy Surgery Division, Wound Closure Division, Biosurgery Division, Surgical Product Expansion Division (i.e. Wide Area Market Division), Strategic Marketing Division, and Robotics and Digitalization Division.

01. Adjustment of the Organizational Structure of the Surgical Division
Given the rapid changes in policy environment and the new trend of market competition, Johnson&Johnson Medical Technology firmly believes that the Surgical Division's continued leadership in the market in the new era is an important cornerstone for winning the Chinese market and the future. To this end, the company has launched the "Yaoying 2030" surgical division strategy, aiming to accelerate the transformation of the GTM model and cover more customers and patients with better and faster services.

In the new stage of development, Johnson&Johnson Medical Technology not only needs to consolidate and expand its existing advantages in the core market, but also seize the opportunities in the second and third tier markets, accelerate market penetration, and broaden its territory in the wide market. To this end, the company will rely on innovative methods, dedicated teams, and fully leverage the synergies of One Surgery to promote the in-depth development of mature businesses, while establishing surgical robots and digital innovation businesses.

Starting from January 1, 2025, the Surgery Division will be reorganized into six major departments: Minimally Invasive and Energy Surgery Division, Wound Closure Division, Biosurgery Division, Surgical Product Expansion Division (i.e. Wide Area Market Division), Strategic Marketing Division, and Robotics and Digitalization Division. Each department will be led by the following leaders:

The Minimally Invasive and Energy Surgery Division will be led by Chen Songxin, the current Senior Director of the Biosurgery Division.

The Surgical Full Product Expansion Division, as a newly established department, aims to tap into the potential of the wide market and will be led by Gao Fei, the current National Sales Director of the Biosurgery Division, as the Senior Director.

The Surgical Strategic Marketing Department will be led by Chen Jingfeng, the current Director of Market Access for the Minimally Invasive and Energy Surgery Division. He will leverage the resources and advantages of One Surgery to lead the team in developing clear market strategies, leading new product development and digital surgical construction, and providing momentum for the sustained growth of the surgical business.

The positions of the heads of the Wound Closure Division, Biosurgery Division, and Robotics and Digitalization Division are currently pending announcement, and the company will announce the relevant appointments at a later time.

In addition, Chen Xiaoming, Senior Director of the MONARCH Department of Surgery at Johnson&Johnson Medical Technology China, has decided to resign and seek new career development opportunities. He will end his job at Johnson&Johnson on December 31, 2024, and will work closely with the team during this period to ensure a smooth handover of work.

02. There have been many personnel changes this year
Johnson&Johnson Medical Technology has undergone significant personnel changes in the past year.

Last week, Larry Jones, Global Vice President and Group Chief Information Officer of Johnson&Johnson Medical Technology, will retire from Johnson&Johnson's medical device business. The details of when and when the official resignation will take place, or who will take over, are still unknown.

Last year, Ashley McEvoy announced her resignation as the Global Chair of Johnson&Johnson Medical Technology. She continued to serve as a consultant until February 2024, after which Tim Schmid took over as the head of the medical device business.

In August of this year, Peter Fasolo, Executive Vice President and Chief Human Resources Officer who has been working at Johnson&Johnson for nearly 20 years, plans to retire at the end of this year. Peter Fasolo has been working at Johnson&Johnson for nearly 20 years and plans to retire at the end of this year. The company has chosen Kristen Mulholland to replace him, effective from October 1st. Fasuolo and Muholland will collaborate during a transitional period until Fasuolo officially retires.

In addition, Johnson&Johnson China also has multiple personnel changes:
 In August of this year, Kevin Chen, General Manager and Head of External Affairs and Market Access of Johnson&Johnson's Cardiovascular and Professional Solutions Division in China, submitted his resignation to the company and sought opportunities for external development. He worked at Johnson&Johnson until September 16, 2024. During the transition phase, Edward Zhou will temporarily take over the management of the Cardiovascular and Professional Solutions Division, as well as the External Affairs and Market Access Department. Chen Chuhui joined Johnson&Johnson in 2009 and has held management positions in the ASP business unit, Endo business unit, ultrasonic knife business unit, as well as the Gynecologe and Manto business units. After returning to Johnson&Johnson in 2015, he also served as an important leader in channel management, strategic customer, operations, and professional education.
 In July, Johnson&Johnson announced that Edward Zhou would assume the position of President of Johnson&Johnson Medical Technology China from July 25, 2024, and become a member of the Johnson&Johnson Medical Technology Asia Pacific leadership team. Zhou Mintao has nearly 30 years of work experience at Johnson&Johnson. He joined Johnson&Johnson's consumer goods business as a sales representative in 1992 and later served as the general manager of Johnson&Johnson's consumer goods business in Singapore. After returning to China, he served as the General Manager of Johnson&Johnson's Consumer Products Business in China. In 2015, he served as the Vice President of the Surgical Business Department of the Care Health Division, and in 2016, he became the General Manager of the Care Health Division in China.
 In April, Johnson&Johnson announced the departure of Song Weiqun, Chairman of the China region and President of Johnson&Johnson Medical Technology China. In 2003, Song Weiqun joined Johnson&Johnson as the only global management trainee at the company's headquarters in the United States. Will Song has only worked for one company to date: Johnson&Johnson. Johnson&Johnson's first locally born Chinese regional chairman.
 In April, Johnson&Johnson announced that Ronnie Chen would serve as the head of human resources for Johnson&Johnson Medical Technology China&OneHR China. Chen Yanli is the former vice president of talent and organizational culture in China of Roche Pharmaceuticals and the head of the Key Account Management Department of China Market Access Hospital.
 At the end of March, Johnson&Johnson Medical Technology announced the appointment of Tulio Oliveira as the new General Manager of its Surgical Division in China. Prior to joining the Chinese team, Tulio served as the Global Head of Advanced Staplement Surgery at Johnson&Johnson Medical Technology. Tulio joined Johnson&Johnson in 2003 as a sales representative for the Brazilian market, working in Brazil, the United States, Chile, and Argentina. His responsibilities span across sales, marketing, new business development, global strategic marketing, strategic planning, and comprehensive management.

Source: http://qixieke.com/Font/index/detailPage.html?id=3250-19